Table 3.
Clinical features of kinase fusion-related papillary thyroid carcinomas in published series
| Study | Queried kinases | %T1-T2 | %T3-T4 | %N1 | %M1 |
|---|---|---|---|---|---|
| Adult | |||||
| Chu et al. | ALK, BRAF, MET, NTRK1/2/3, RET, ROS1 | 37 | 61 | 79 | 6 |
| Chou et al. | ALK | 45 | 55 | 27 | 0 |
| Kong et al. | NTRK1/2/3 | 53 | 47 | 83 | 11 |
| Nozaki et al. | ALK, NTRK1/3, ROS1 | 75 | 25 | 75 | 0 |
| Panebianco et al. | ALK | 89 | 11 | 30 | 0 |
| Lee et al. | NTRK1/2/3 | 92 | 8 | 42 | 8 |
| Park et al. | ALK | 100 | 0 | 50 | 0 |
| Pediatric | |||||
| Cordioli et al. | BRAF, NTRK3, RET | 35 | 65 | 88 | 35 |
| Pekova et al. | ALK, BRAF, MET, NTRK1/2/3, RET, ROS1 | 44 | 56 | 81 | 17 |
| Franco et al. | ALK, BRAF, MET, NTRK1/2/3, RET, ROS1 | 47 | 49 | 93 | 40 |
| Ricarte-Filho et al. | NTRK1/2/3 | 55 | 45 | 80 | 45 |
| Prasad et al. | ALK, BRAF, MET, NTRK1/3, RET | 77 | 23 | 69 | 0 |
| Rogounovitch et al. | BRAF, NTRK3, RET | 78 | 22 | 83 | 6 |
| Alzahrani et al. | ALK, BRAF, MET, NTRK1/2/3, RET, ROS1 | 75 | 15 | 85 | 15 |